Business Context and Reporting Period
Company: Varex Imaging Corp (VREX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended July 4, 2025 (Q3 Fiscal 2025)
Business Overview: Varex designs, manufactures, and sells X-ray imaging components for medical diagnostic, radiation therapy, dental, and veterinary equipment, as well as industrial security and inspection systems. The company operates through two segments: Medical and Industrial.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues, Net | $203.0 | $209.1 | $615.7 | $605.3 |
| Gross Profit | $67.5 | $66.9 | $212.7 | $189.8 |
| Gross Margin | 33.3% | 32.0% | 34.5% | 31.4% |
| Operating Income (Loss) | $(80.7) | $9.3 | $(47.4) | $21.2 |
| Net Income (Loss) | $(89.1) | $1.5 | $(82.1) | $2.7 |
| Diluted EPS | $(2.15) | $0.03 | $(2.00) | $0.06 |
| Cash & Equivalents | $136.4 | $168.7 | Balance Sheet Item | |
| Total Debt (Net) | $367.5 | $443.4 | Balance Sheet Item | |
| Operating Cash Flow (9M) | $33.8 | $21.4 |
Material Changes vs. Prior Period
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $93.9 million in Q3 2025 related to the Medical reporting unit. This charge was the primary driver of the operating loss and net loss for the quarter and the nine-month period.
- Revenue Trends: Total revenue decreased 2.9% year-over-year in Q3 ($203.0M vs $209.1M) but increased 1.7% for the nine-month period ($615.7M vs $605.3M). Medical segment revenue declined 4.4% in Q3, while Industrial revenue grew 0.7%.
- Debt Restructuring: The company repaid $200.0 million in Convertible Senior Unsecured Notes at maturity in June 2025. This was partially funded by the issuance of $125.0 million in Senior Secured Notes in December 2024. Total net debt decreased from $443.4 million to $367.5 million.
- Accounting Revision: The company identified an accounting error regarding deferred tax assets and liabilities in prior periods. Prior period financial statements were revised, though management determined the impact was not material individually or in aggregate for prior periods.
Guidance, Outlook, and Risks
- Impairment Drivers: The goodwill impairment was triggered by a sustained decrease in stock price and market capitalization, downward revisions to long-term forecasts, and macroeconomic headwinds including tariffs and the China Ministry of Commerce (MOFCOM) investigations into medical products.
- Trade Environment: The company faces significant risks from U.S.-China trade tensions. MOFCOM initiated two investigations regarding X-ray tubes and CT tube inserts imported into China, which are currently paused. The company anticipates these could take approximately one year to resolve if recommenced.
- Liquidity: Management believes operating cash flow, cash on hand, and availability under the Revolving Credit Facility ($154.8 million available) are sufficient to meet obligations for the next 12 months.
- Backlog: Estimated total backlog as of July 4, 2025, was approximately $284 million.
- Legal Proceedings: Ongoing disputes exist regarding joint ventures (VEC Imaging and Varex Imaging Arabia) and intellectual property matters in Germany and the U.S., which could divert management attention and increase costs.
Investor Verification Checklist
- Goodwill Impairment Sustainability: Verify if the $93.9 million impairment is a one-time event or if further impairments are likely given the continued decline in stock price and forecast revisions.
- MOFCOM Investigation Outcome: Monitor the status of the China Ministry of Commerce investigations, as a negative outcome could materially impact the 10% of revenue derived from medical X-ray tube imports to China.
- Debt Covenants: Review compliance with the Revolving Credit Facility covenants, specifically the consolidated total net leverage ratio (max 3.75:1.00) and fixed charge coverage ratio (min 1.25:1.00), given the recent operating losses.
- Customer Concentration: Note that one customer (Canon Medical Systems) accounted for 17.8% of revenue in Q3 2025; assess the risk of order delays or cancellations from this major OEM.
- Tax Rate Volatility: Review the impact of the non-deductible goodwill impairment and the new U.S. tax legislation (OBBBA) on future effective tax rates.